NCT02528643 - A Study to Assess the Efficacy and Safety of Enzalutamide in Subjects With Advanced Hepatocellular Carcinoma | Biotech Hunter

Enrollment

165

Participants

Timeline

Start Date

November 9, 2015

Primary Completion Date

October 2, 2017

Study Completion Date

February 9, 2021

Conditions

Advanced Hepatocellular Carcinoma

Interventions

DRUG

Enzalutamide

Oral capsule

DRUG

Placebo

Oral capsule

Trial Locations (38)

640

Site TW88603, Douliu

704

Site TW88606, Tainan City

710

Site TW88605, Tainan City

10048

Site TW88604, Taipei

14004

Site ES34006, Córdoba

19104

Site US10014, Philadelphia

Site US10019, Philadelphia

20089

Site IT39008, Rozzano

20122

Site IT39006, Milan

20132

Site IT39002, Milan

27100

Site IT39004, Pavia

28222

Site ES34004, Madrid

35128

Site IT39011, Padua

60077

Site US10009, Skokie

94115

Site US10003, San Francisco

97239

Site US10008, Portland

999077

Site HK85202, Kowloon

Site HK85204, Shatin

55455-0362

Site US10017, Minneapolis

03756-1000

Site US10021, Lebanon

53226-3522

Site US10016, Milwaukee

M5G2C4

Site CA15001, Toronto

H3T 1E2

Site CA15002, Montreal

H4A 3J1

Site CA15003, Montreal

Unknown

Site IT39005, Benevento

00927

Site US10001, San Juan

013620

Site KR82002, Seongnam-si

135-710

Site KR82005, Seoul

03080

Site KR82006, Seoul

03722

Site KR82007, Seoul

05505

Site KR82004, Seoul

06591

Site KR82001, Seoul

08035

Site ES34003, Barcelona

B15 2WB

Site GB44007, Birmingham

SE5 9RS

Site GB44004, London

W12 OHS

Site GB44008, London

M20 4BX

Site GB44005, Manchester

CH63 4JY

Site GB44002, Metropolitan Borough of Wirral